GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acticor Biotech SA (XPAR:ALACT) » Definitions » EPS (Diluted)

Acticor Biotech (XPAR:ALACT) EPS (Diluted) : €-1.67 (TTM As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Acticor Biotech EPS (Diluted)?

Acticor Biotech's Earnings per Share (Diluted) for the six months ended in Jun. 2023 was €-0.87. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €-1.67.

Acticor Biotech's EPS (Basic) for the six months ended in Jun. 2023 was €-0.87. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was €-1.67.

Acticor Biotech's EPS without NRI for the six months ended in Jun. 2023 was €-0.87. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was €-1.67.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Acticor Biotech EPS (Diluted) Historical Data

The historical data trend for Acticor Biotech's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acticor Biotech EPS (Diluted) Chart

Acticor Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS (Diluted)
Get a 7-Day Free Trial -0.57 -0.48 -0.73 -1.62 -1.49

Acticor Biotech Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only -0.56 -0.64 -0.69 -0.80 -0.87

Competitive Comparison of Acticor Biotech's EPS (Diluted)

For the Biotechnology subindustry, Acticor Biotech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acticor Biotech's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acticor Biotech's PE Ratio distribution charts can be found below:

* The bar in red indicates where Acticor Biotech's PE Ratio falls into.



Acticor Biotech EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Acticor Biotech's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-15.878-0)/10.546
=-1.51

Acticor Biotech's Diluted EPS for the quarter that ended in Jun. 2023 is calculated as

Diluted EPS (Q: Jun. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-10.081-0)/11.632
=-0.87

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acticor Biotech  (XPAR:ALACT) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Acticor Biotech EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Acticor Biotech's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Acticor Biotech (XPAR:ALACT) Business Description

Traded in Other Exchanges
Address
82 Avenue du Maine, Wojo Building, Paris, FRA, 75014
Acticor Biotech SA is a clinical stage biopharmaceutical company. It is developing a treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke.

Acticor Biotech (XPAR:ALACT) Headlines

No Headlines